// App-Quantinova.ai

217 : Randomized phase II trial of docetaxel plus prednisolone with or without androgen deprivation treatment in castration-resistant prostate cancer.

Researchers

Presenter

  • Jae Ho Jeong

Principal Investigators

  • Hyejung Hyun

  • In Gab Jeong

  • Jun Hyuk Hong

  • Hanjong Ahn

  • Jae-Lyun Lee

Medical Centers

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of (South), Korea

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of (South), Korea

Locations

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Prednisolone

  • Leuprolide acetate

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT01487902

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved